Pay in 4 interest-free payments of $5.83 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
Both medications are typically taken once a week using a convenient pre-filled pen
Allison Whitten AstraZeneca reports mixed Phase 3 results across oncology and rare disease AstraZeneca reported mixed late-stage clinical results, with its Claudin 18.2-targeting antibody-drug conjugate sonesitatug vedotin meeting its primary endpoint in patients with previously treated advanced gastric cancer, while rare disease therapy Ultomiris missed the primary endpoint in a Phase 3 trial for thrombotic microangiopathy following haematopoietic stem cell transplantation (HSCT-TMA)
You can upgrade with hormone optimization, gut health repair, genetic insights, and IV nutrient supportall offered in-house, and all backed by actual science, not wellness fairy dust. We built this place to cut through the noise
Additionally, eligible Medicare Part D individuals may be able to get Foundayo for $50 per month, beginning July 1, 2026
US$ 29.88
US$ 20.75
US$ 24.54
US$ 28.83
